Keith Gottesdiener, Prime Medicine CEO
September 30, 2024 07:35 AM EDTUpdated 02:27 PM
Deals
R&D

Up­dat­ed: Prime Med­i­cine whit­tles down pipeline, signs gene edit­ing deal with Bris­tol My­ers

Lei Lei Wu

News Reporter

Prime Med­i­cine is cut­ting its pipeline, but gain­ing a part­ner.

The gene edit­ing com­pa­ny, which once boast­ed a pipeline of 18 pro­grams, is now fo­cus­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Trump 2.0 blog: Way­back Ma­chine is in­suf­fi­cient for US health da­ta, judge says

Pfiz­er’s prostate can­cer da­ta leak shows promis­ing re­sults in ear­ly-stage study

What will phar­ma's share buy­back shop­ping spree mean for M&A?

Bio­haven lands pri­or­i­ty re­view on sec­ond-chance ap­pli­ca­tion for neu­rode­gen­er­a­tive drug

Tra­vere plans to seek ex­pand­ed la­bel for kid­ney drug de­spite failed tri­al

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times